Compare SLGL & QIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLGL | QIPT |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | Israel | United States |
| Employees | N/A | 1600 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.7M | 161.9M |
| IPO Year | 2016 | 2012 |
| Metric | SLGL | QIPT |
|---|---|---|
| Price | $83.70 | $3.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $110.00 | $3.83 |
| AVG Volume (30 Days) | 11.7K | ★ 330.5K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $245,359,000.00 |
| Revenue This Year | $122.71 | $28.30 |
| Revenue Next Year | N/A | $1.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $1.37 |
| 52 Week High | $97.97 | $3.65 |
| Indicator | SLGL | QIPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 72.69 |
| Support Level | $32.56 | $3.55 |
| Resistance Level | $97.97 | N/A |
| Average True Range (ATR) | 10.01 | 0.02 |
| MACD | -1.12 | -0.00 |
| Stochastic Oscillator | 56.18 | 80.00 |
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Quipt Home Medical Corp is a provider of durable medical equipment (DME) and home medical equipment (HME) in the United States. The Company specializes in delivering in-home treatments for the management of chronic conditions, with a primary focus on respiratory diseases, and supports patients with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Its products and services include Sleep Apnea and PAP treatment, home medical equipment, home ventilation, and custom mobility solutions. The Company operates in a single business segment, comprising the sale and rental of medical equipment and related devices, and serves patients across 27 states in the United States.